BIOCON2023-04-012023-06-30 BIOCON2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member BIOCON2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member BIOCON2023-06-30 BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue01Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue02Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue03Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue04Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults01Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults02Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults03Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults04Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets01Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets02Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets03Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets04Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member BIOCON2023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member BIOCON2023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities03Member BIOCON2023-06-30in-bse-fin:OneReportableSegmentLiabilities03Member BIOCON2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities04Member BIOCON2023-06-30in-bse-fin:OneReportableSegmentLiabilities04Member BIOCON2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member BIOCON2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532523 BIOCON NOTLISTED Biocon Limited Equity 2023-04-01 2024-03-31 2023-08-10 2023-07-21 INR Millions First quarter 17:45:00 19:25:00 2023-08-10 2023-08-10 Not applicable Multi segment 2023-04-01 2023-06-30 Unaudited Consolidated 34226000000.00 935000000.00 35161000000.00 10256000000.00 2775000000.00 -935000000.00 5793000000.00 2330000000.00 3580000000.00 9193000000.00 32992000000.00 2169000000.00 0.00 2169000000.00 434000000.00 -86000000.00 348000000.00 0.00 1821000000.00 0.00 0.00 0.00 -332000000.00 1489000000.00 1709000000.00 3198000000.00 1014000000.00 475000000.00 2116000000.00 1082000000.00 6003000000.00 5 0.85 0.85 0.00 0.00 0.85 0.85 Due to size constraints, we are unable to provide full Notes in XBRL. Please refer Outcome of Board Meeying dated August 10, 2023 for full notes to the financial results for quarter ended 30.06.2023. Less: Recovery of cost from co-development partners (net) -49000000.00 Other 9242000000.00 Biosimilars 20148000000.00 Generics 7003000000.00 Novel Biologics 0.00 Research services 8081000000.00 35232000000.00 1006000000.00 34226000000.00 Biosimilars 243000000.00 Generics 641000000.00 Novel Biologics -62000000.00 Research services 1229000000.00 2051000000.00 0.00 214000000.00 Due to size constraints, we are unable to provide full Notes in XBRL. Please refer Outcome of Board Meeying dated August 10, 2023 for full notes to the financial results for quarter ended 30.06.2023. 1837000000.00 Biosimilars 407959000000.00 Generics 61497000000.00 Novel Biologics 1570000000.00 Research services 60610000000.00 531636000000.00 620000000.00 532256000000.00 Biosimilars 237104000000.00 Generics 19029000000.00 Novel Biologics 296000000.00 Research services 22165000000.00 278594000000.00 12771000000.00 291365000000.00 Items that will not be reclassified to profit or loss 13000000.00 13000000.00 4000000.00 Items that will be reclassified to profit or loss 2029000000.00 2029000000.00 329000000.00